Hydrophilic Antibody-Drug Conjugates for High Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drug conjugates face challenges with higher drug loadings, which lead to faster clearance and narrower therapeutic indices, compromising pharmacokinetic properties and efficacy, despite efforts to include solubilizing groups like polyethylene glycol polymers.
Innovation Solution
Designing hydrophilic Ligand-Linker-Drug Conjugates that maintain the pharmacokinetic properties of the unconjugated targeting agent by ensuring the conjugates have a hydrophilicity similar to the targeting agent, allowing for higher drug loadings without impairing desirable properties, such as reduced clearance and increased exposure to target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If higher drug loadings are used in antibody-drug conjugates, then the cytotoxic activity and delivery efficiency are improved, but the clearance rate increases and therapeutic index narrows
Solution Approach 1:
The patent changes the hydrophilicity parameter of the conjugate by incorporating hydrophilic linkers and solubilizing groups, which fundamentally alters how the conjugate interacts with biological systems, enabling higher drug loading without proportional increase in clearance
Solution Approach 2:
The invention creates a composite structure combining antibody, hydrophilic linker, and cytotoxic drug, where the hydrophilic components act as solubilizing agents that prevent aggregation and enhance circulation stability, allowing high drug loading while maintaining favorable pharmacokinetics
2Reliability
If solubilizing groups like polyethylene glycol polymers are included to improve pharmacokinetics, then clearance is reduced, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the conjugate into distinct functional modules: antibody component, hydrophilic linker component, and drug component, allowing independent optimization of each segment and simplifying the overall design compared to using large polymer chains
Solution Approach 2:
Instead of changing the overall size or complexity of the conjugate, the invention changes the hydrophilicity parameter through specific linker design, achieving improved pharmacokinetics without increasing structural complexity
3Reliability
If higher drug loadings are used, then the therapeutic index improves, but the manufacturing precision and control over conjugate heterogeneity become more difficult
Solution Approach 1:
The patent applies local quality modification by introducing hydrophilic characteristics specifically at the linker region, which locally enhances solubility and pharmacokinetic properties without requiring uniform modification throughout the entire conjugate structure, thereby maintaining manufacturing precision even at high drug loadings
Data Source
AI summary
Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.